GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » Price-to-Operating-Cash-Flow

Cardiol Therapeutics (TSX:CRDL) Price-to-Operating-Cash-Flow : (As of Jun. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-06-05), Cardiol Therapeutics's share price is C$3.60. Cardiol Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.34. Hence, Cardiol Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Cardiol Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

TSX:CRDL's Price-to-Operating-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 16.105
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Cardiol Therapeutics's Cash Flow from Operations per share for the three months ended in Mar. 2024 was C$-0.10. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.34.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -8.50% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 6.70% per year.

During the past 7 years, Cardiol Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 8.40% per year. The lowest was -75.10% per year. And the median was -4.00% per year.


Cardiol Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Cardiol Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics Price-to-Operating-Cash-Flow Chart

Cardiol Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

Cardiol Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cardiol Therapeutics's Price-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiol Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cardiol Therapeutics's Price-to-Operating-Cash-Flow falls into.



Cardiol Therapeutics Price-to-Operating-Cash-Flow Calculation

Cardiol Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=3.60/-0.339
=

Cardiol Therapeutics's Share Price of today is C$3.60.
Cardiol Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.34.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Cardiol Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiol Therapeutics (TSX:CRDL) Business Description

Traded in Other Exchanges
Address
2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Executives
Guillermo Torre Senior Officer

Cardiol Therapeutics (TSX:CRDL) Headlines

From GuruFocus

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-13-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 05-24-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-03-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-23-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 07-03-2022

Heart Failure and CBD -- CFN Media

By Marketwired Marketwired 02-20-2019